Clinical Trials Browser

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03782207 2026-01-08

IMreal

Active not recruiting

2,756 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT03041311 2025-09-25

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

Phase 2 Completed

107 enrolled 42 charts

Thoracic

Small Cell Lung Carcinoma

NCT05652686 2025-09-23

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Phase 1/2 Recruiting

203 enrolled

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05224141 2025-07-08

KEYVIBE-008

Phase 3 Active not recruiting

460 enrolled 18 charts

Thoracic

Small Cell Lung Carcinoma

NCT04101357 2025-03-18

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

Phase 1/2 Terminated

54 enrolled 30 charts

Thoracic

Small Cell Lung Carcinoma

NCT04622228 2024-07-29

Match

Phase 2 Completed

56 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04028050 2024-07-16

MAURIS

Phase 3 Completed

155 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04308785 2023-10-23

A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer

Phase 2 Terminated

24 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT02763579 2023-07-28

IMpower133

Phase 3 Completed

503 enrolled 23 charts 2 FDA

Thoracic

Small Cell Lung Carcinoma

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Phase 1 Completed

37 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03232593 2022-08-24

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

Completed

1,758 enrolled

BreastGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04422210 2021-11-08

A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

Phase 1 Terminated

2 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Clinical Trials

DAREONᵀᴹ-8

SEZanne

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

SKYSCRAPER-02

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

IMforte

MK-6070-001

SKYSCRAPER-02C

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

(DeLLphi-310)

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

IMreal

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

KEYVIBE-008

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

Match

MAURIS

A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer

IMpower133

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.